ID   Ma-Mel-86b
AC   CVCL_A222
SY   Ma-Mel_86b; Ma-Mel 86b
DR   cancercelllines; CVCL_A222
DR   GEO; GSM109093
DR   GEO; GSM2135604
DR   Progenetix; CVCL_A222
DR   Wikidata; Q54903861
RX   PubMed=16827748;
RX   PubMed=27261508;
CC   Characteristics: Has lost HLA class I surface expression due to the deletion of B2M (PubMed=27261508).
CC   Sequence variation: Gene deletion; HGNC; HGNC:914; B2M; Zygosity=Homozygous (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508).
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
DI   NCIt; C4225; Cutaneous nodular melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A221 ! Ma-Mel-86a
OI   CVCL_C7TP ! Ma-Mel-86c
OI   CVCL_C7TQ ! Ma-Mel-86f
SX   Female
AG   35Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 14
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R.,
RA   Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D.,
RA   Dummer R.;
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=27261508; DOI=10.1158/0008-5472.CAN-16-0008;
RA   Zhao F., Sucker A., Horn S., Heeke C., Bielefeld N., Schrors B.,
RA   Bicker A., Lindemann M., Roesch A., Gaudernack G., Stiller M.,
RA   Becker J.C., Lennerz V., Wolfel T., Schadendorf D., Griewank K.G.,
RA   Paschen A.;
RT   "Melanoma lesions independently acquire T-cell resistance during
RT   metastatic latency.";
RL   Cancer Res. 76:4347-4358(2016).
//